Author:
Suzuki Daisuke,Kobayashi Ryoji,Sano Hirozumi,Kishimoto Kenji,Yasuda Kazue,Nakanishi Masanori,Nagashima Tetsuro,Kobayashi Kunihiko
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Stine KC, Saylors RL, Williams LL, Becton DL. 2-Chlorodeoxyadenosine (2-CdA) for the treatment of refractory or recurrent Langerhans cell histiocytosis (LCH) in pediatric patients. Med Pediatr Oncol. 1997;29:288–92.
2. Apollonsky N, Lipton JM. Treatment of refractory Langerhans cell histiocytosis (LCH) with a combination of 2-chlorodeoxyadenosine and cytosine arabinoside. J Pediatr Hematol Oncol. 2009;31:53–6.
3. Weitzman S, Wayne AS, Arceci R, Lipton JM, Whitlock JA. Nucleoside analogues in the therapy of Langerhans cell histiocytosis: a survey of members of the histiocyte society and review of the literature. Med Pediatr Oncol. 1999;33:476–81.
4. Jager G, Hofler G, Linkesch W, Neumeister P. Occurrence of a myelodysplastic syndrome (MDS) during first-line 2-chlorodeoxyadenosine (2-CdA) treatement of a low-grade gastrointestinal MALT lymphoma. Case report and review of the literature. Haematologica. 2004;89:e1–3.
5. Van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A. Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol. 1999;105:268–70.
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献